Tags

Type your tag names separated by a space and hit enter

Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.
Diabet Med. 2011 Dec; 28(12):1530-6.DM

Abstract

AIMS

To evaluate the long-lasting immunogenicity and safety of a pandemic vaccine co-administered with a seasonal influenza vaccine in young subjects with Type 1 diabetes.

METHODS

Eighty patients (mean age: 16.7 ± 5.5 years, disease duration: 10.2 ± 4.7 years) were randomly assigned to receive a single or a double dose (1 month apart) of MF59-adjuvanted influenza A(H1N1) vaccine, simultaneously with a single dose of a virosome-adjuvanted trivalent influenza vaccine for the 2009-2010 season.

RESULTS

One month after immunization, the rate of seroconversion to 2009 pandemic A(H1N1) was 92.5% with an overall 100% proportion of vaccinees with protective antibody titres (≥ 1:40). No significant differences were observed between vaccinees who received the one-dose or the two-dose schedule. Seasonal vaccine induced a significant increase of both seroprotection rates and antibody levels. Local adverse events at the injection site of pandemic and seasonal vaccines were reported by 66.3% and 50% of subjects, respectively. Solicited systemic adverse events, mainly mild in intensity, were reported by 26.7% of vaccinees. No subjects had an influenza-like illness during the 6-month follow-up.

CONCLUSIONS

One injection of 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine is immunogenic and safe in young patients with Type 1 diabetes who are at increased risk of influenza morbidities. Pandemic vaccine can be safely co-administered with seasonal influenza vaccine.

Authors+Show Affiliations

Department of Paediatrics, Università degli Studi di Milano, Ospedale Luigi Sacco, Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

21916971

Citation

Zuccotti, G V., et al. "Long-lasting Immunogenicity and Safety of a 2009 Pandemic Influenza A(H1N1) MF59-adjuvanted Vaccine when Co-administered With a 2009-2010 Seasonal Influenza Vaccine in Young Patients With Type 1 Diabetes Mellitus." Diabetic Medicine : a Journal of the British Diabetic Association, vol. 28, no. 12, 2011, pp. 1530-6.
Zuccotti GV, Pariani E, Scaramuzza A, et al. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. Diabet Med. 2011;28(12):1530-6.
Zuccotti, G. V., Pariani, E., Scaramuzza, A., Santoro, L., Giani, E., Macedoni, M., Gazzarri, A., Anselmi, G., Amendola, A., & Zanetti, A. (2011). Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. Diabetic Medicine : a Journal of the British Diabetic Association, 28(12), 1530-6. https://doi.org/10.1111/j.1464-5491.2011.03449.x
Zuccotti GV, et al. Long-lasting Immunogenicity and Safety of a 2009 Pandemic Influenza A(H1N1) MF59-adjuvanted Vaccine when Co-administered With a 2009-2010 Seasonal Influenza Vaccine in Young Patients With Type 1 Diabetes Mellitus. Diabet Med. 2011;28(12):1530-6. PubMed PMID: 21916971.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. AU - Zuccotti,G V, AU - Pariani,E, AU - Scaramuzza,A, AU - Santoro,L, AU - Giani,E, AU - Macedoni,M, AU - Gazzarri,A, AU - Anselmi,G, AU - Amendola,A, AU - Zanetti,A, PY - 2011/9/16/entrez PY - 2011/9/16/pubmed PY - 2012/12/12/medline SP - 1530 EP - 6 JF - Diabetic medicine : a journal of the British Diabetic Association JO - Diabet Med VL - 28 IS - 12 N2 - AIMS: To evaluate the long-lasting immunogenicity and safety of a pandemic vaccine co-administered with a seasonal influenza vaccine in young subjects with Type 1 diabetes. METHODS: Eighty patients (mean age: 16.7 ± 5.5 years, disease duration: 10.2 ± 4.7 years) were randomly assigned to receive a single or a double dose (1 month apart) of MF59-adjuvanted influenza A(H1N1) vaccine, simultaneously with a single dose of a virosome-adjuvanted trivalent influenza vaccine for the 2009-2010 season. RESULTS: One month after immunization, the rate of seroconversion to 2009 pandemic A(H1N1) was 92.5% with an overall 100% proportion of vaccinees with protective antibody titres (≥ 1:40). No significant differences were observed between vaccinees who received the one-dose or the two-dose schedule. Seasonal vaccine induced a significant increase of both seroprotection rates and antibody levels. Local adverse events at the injection site of pandemic and seasonal vaccines were reported by 66.3% and 50% of subjects, respectively. Solicited systemic adverse events, mainly mild in intensity, were reported by 26.7% of vaccinees. No subjects had an influenza-like illness during the 6-month follow-up. CONCLUSIONS: One injection of 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine is immunogenic and safe in young patients with Type 1 diabetes who are at increased risk of influenza morbidities. Pandemic vaccine can be safely co-administered with seasonal influenza vaccine. SN - 1464-5491 UR - https://www.unboundmedicine.com/medline/citation/21916971/Long_lasting_immunogenicity_and_safety_of_a_2009_pandemic_influenza_A_H1N1__MF59_adjuvanted_vaccine_when_co_administered_with_a_2009_2010_seasonal_influenza_vaccine_in_young_patients_with_type_1_diabetes_mellitus_ L2 - https://doi.org/10.1111/j.1464-5491.2011.03449.x DB - PRIME DP - Unbound Medicine ER -